Air Street Capital

InVitro Capital is a venture studio that creates, builds, and exits companies in the AI and B2B space. With a primary focus on Healthcare and SaaS, Invitro has developed a unique recipe to de-risk startup innovation and help aspiring exceptional entrepreneurs identify and capitalize on promising opportunities. At InVitro, we believe that the best startups are built by teams with deep domain expertise and a passion for solving real-world problems. That's why we invest in and partner with entrepreneurs who have a proven track record of success and a vision for the future. We provide our portfolio companies with the operational muscles and support they need to succeed, including: Seed funding. Access to our network of mentors and advisors. Expertise in tech, marketing, sales, and business development. Help with go-to-market strategy. We also have a unique approach to exits. Instead of waiting for a large tech company to come knocking, we actively work with our portfolio companies to develop and execute their own exit strategies. This allows us to maximize returns for our investors and give our entrepreneurs the freedom to pursue their next big idea

Investment arm of Enterprise Singapore, nurturing Singapore-based tech startups with intellectual property and global market potential. SEEDS Capital was founded in 2001 to foster entrepreneurship in Singapore when the technology and startup ecosystem was nascent. Today, Singapore is ranked first in Asia and seventh globally in Startup Blink’s Global Startup Ecosystem Index 2022. SEEDS is one of the most active investors in Singapore according to Tech In Asia. As the investment arm of Enterprise Singapore, SEEDS catalyses private sector investments into Singapore-based, early-stage technology startups that are pioneering scientific and engineering solutions. We co-invest with institutional investors such as venture capital funds (VCs), corporate venture capital arms (CVCs) and family offices in innovative startups with strong intellectual content and global market potential. As early-stage investors, we invest in the first and second institutional rounds of technology startups. Our focus sectors are Advanced Manufacturing & Engineering, Health & Biomedical Sciences and Urban Solutions & Sustainability. We also look at emerging areas such as Agri-tech, Artificial Intelligence, Blockchain, Quantum and Space Technologies. Post-investment, we leverage Enterprise Singapore’s network across industries and global overseas centres to add value to our portfolio companies. Since 2017, we have deployed more than S$220 million and stimulated more than S$950 million of private sector investments into more than 160 companies. Learn more about our co-investment partners and portfolio startups.

Flex Capital is a $200 million seed-stage venture fund. We’re capital for founders by founders. Our three general partners are serial entrepreneurs: Tod Sacerdoti (BrightRoll, Pipedream), Auren Hoffman (LiveRamp, SafeGraph), and Paul Johnson (Lemonaid Health). Our goal is to empower the next generation of founders and iconic companies by being the most impactful early-stage investor on their cap table. We view founders as peers, not investments, and build long-term partnerships spanning decades. Flex has been fortunate to back companies such as Angellist, Applovin, Bolt.new, Chime, CodeRabbit, Datavant, Mercury, Perplexity, Replit, Vercel and many more.

We have invested in more than 90 companies since 2016, including Pinterest, Compass, Hippo, Ro, Carta, Dutchie, Anduril, Varda Space Industries, Ghost, Front, Esusu, OKCredit, and Unqork. Additionally, through our subsidiary fund, New Slate Ventures, we have financed films, documentaries, and limited series that have been acquired by Apple, Netflix, and Disney. Based in New York City, we invest globally. Backstory Sinai Capital Partners was founded in 2017. We raised $100 million and built a talented team of young investors with offices in New York, Palo Alto, and Los Angeles. We made over 90 investments, realized 11 exits, and achieved a 1X return on our first fund within two years. In 2019, we raised $100 million for a subsidiary of Sinai Capital called New Slate Ventures, with the goal of supplying the many players in the streaming wars with independent content. Our films, series, and documentaries won Academy Award nominations, Golden Globes, Grammy’s, and Emmy’s, and were acquired by the likes of Apple, Disney, and Netflix for multiples of their cost. As a solo GP, I believe boutique, disciplined, early-stage funds with effective managers will generate the best returns for investors in this forthcoming innovation cycle. Throughout my career I’ve nurtured relationships across Silicon Valley, Wall Street, Washington DC, and Hollywood, and aim to leverage this access on behalf of the founders I support. Where to Now? We’re currently in the midst of the greatest acceleration of technological progress since 2010 and the advent of mobile/social computing. New frameworks for problem solving are emerging daily aided by artificial intelligence, CRISPR technologies, climate manipulation, and several other radical new fields previously dismissed as science fiction. When we started Sinai, the prevailing wisdom in Silicon Valley was that “hardware was hard” and that software investments provided much better risk-adjusted opportunities. That assumption is becoming less credible in the current venture capital landscape, with space exploration, brain computer interfaces, driverless electric vehicles, autonomous warfare drones, and nuclear fusion companies all appearing to be increasingly within reach, with potentially transformational impacts on civilization. Sinai’s new focus will be on these harder technical problems, as we believe this is where the majority of the value creation for this next venture cycle will emerge. While we still welcome revenue generating SaaS businesses, its become clearer to us that the best returns come from the most non-obvious ideas in undefined markets and categories. Some of our latest investments include Anduril, Varda, Galvanick, Rangeview, Factory.AI, Science.IO, and several others. We seek to invest in 5-10 companies each year, with average check sizes ranging between $1-5M depending on stage. We’re happy to lead seed rounds where we have high conviction, but prefer to collaborate with our friends at top funds across the globe. We are geographically agnostic, but are most active in New York, San Francisco, Miami, London, and the South Bay of Los Angeles.

Through our deep scientific and industry network we are able to identify transformative life science investments in under-ventured regions of the US and UK, building companies from scratch to create value and shared success. Our international management team has a track record of successfully partnering with scientists and entrepreneurs to develop highly innovative products for the global healthcare market. We leverage our extensive relationships, industry operating experience and a disciplined investment approach to add significant value to our portfolio companies and to generate strong returns on investment for our investors. We believe in working closely with the management of our portfolio companies to drive the translation of their research into world-class businesses. Our global network includes investment professionals, scientists, industry executives, health practitioners, policy experts, regulatory advisors and business development leaders. This strong network contributes significantly to the growth and development of our portfolio companies.

Based in the vibrant and forward-thinking city of Dubai, our venture capital fund is dedicated to identifying and investing in promising startups at various stages of their journey, from pre-Seed to Series B. Our Investment ApproachWe invest across sectors and stages, from pre-Seed/Seed to Series-A & Series-B UAE-centric: we support startups with an existing tie to Dubai and the UAE We back exceptional founders and inspiring teams with excellent execution and decisiveness We emphasize on customer validation: we believe great companies are built around their customer’s needs Founder-centric Ethos: we understand the founder's journey; their vision drives us Active engagement: We actively engage through regular check-ins, strategy sessions, and introductions We have invested in these verticalsFintech EdTech Digital Health Logistics Future of Work Impact AI/ML Consumer E-Commerce